Hung Trinh: Lutathera Cuts Risk of Death by 72% in Neuroendocrine Tumor Treatment

Hung Trinh, Director of Process Development and MFG Science and Technology at Vyriad, posted on LinkedIn:

“NETTER-2 Trial: Lutathera Cuts Risk of Death by 72% in Neuroendocrine Tumor Treatment

Novartis announced groundbreaking results from the NETTER-2 trial, showing Lutathera plus octreotide LAR significantly reduces the risk of death by 72% in patients with advanced GEP neuroendocrine tumors. This first successful Phase III trial of radioligand therapy (RLT) in a first-line setting marks a major advancement in cancer treatment.

In a landmark development for cancer therapy, the Phase III NETTER-2 trial, led by Novartis, demonstrated that Lutathera® plus octreotide LAR significantly extends median progression-free survival to 22.8 months and reduces disease progression or death by 72% in advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

The study’s findings, presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, mark the first successful use of radioligand therapy (RLT) as a first-line treatment.”

Proceed to the article.
Source: Hung Trinh/LinkedIn